(Q33193524)

23 July 2017

1 reference

title

Antibodies as therapeutic agents: vive la renaissance! (English)

1 reference

23 July 2017

1 reference

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

16 March 2024

author name string

L. H. Stockwin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14519077

16 March 2024

S. Holmes

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14519077

16 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

full work available at URL

23 July 2017

http://www.tandfonline.com/doi/pdf/10.1517/14712598.3.7.1133

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Expert Opinion on Biological Therapy

16 March 2024

published in

1 reference

23 July 2017

3

1 reference

23 July 2017

7

1 reference

23 July 2017

1133-1152

1 reference

Emil von Behring and serum therapy.

23 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Replacing the complementarity-determining regions in a human antibody with those from a mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Role of natural and immune IgM antibodies in immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Immunoglobulin D-deficient mice can mount normal immune responses to thymus-independent and -dependent antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Immunoglobulin D (IgD)-deficient mice reveal an auxiliary receptor function for IgD in antigen-mediated recruitment of B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Transcytosis and catabolism of antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Generating binding activities from Escherichia coli by expression of a repertoire of immunoglobulin variable domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Kinetic and affinity limits on antibodies produced during immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Functional proteins from a random-sequence library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Designing and optimizing library selection strategies for generating high-affinity antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Phage antibodies: filamentous phage displaying antibody variable domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Yeast surface display for screening combinatorial polypeptide libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Production of human monoclonal and polyclonal antibodies in TransChromo animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Germ-line transmission and expression of a human-derived yeast artificial chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

21 January 2018

Immunization with DNA.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Combinatorial antibodies against human malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Phage display selection on whole cells yields a peptide specific for melanocortin receptor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

De novo identification of tumor-specific internalizing human antibody-receptor pairs by phage-display methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Natural and designer binding sites made by phage display technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Biophysical methods for the determination of antibody-antigen affinities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

In vitro mechanisms of monoclonal antibody neutralization of alphaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

In vitro antibodies: strategies for production and application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Production of antibodies in plants and their use for global health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

The mechanisms of action of rituximab in the elimination of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Natural and engineered cytotoxic ribonucleases: therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

The ErbB receptors and their role in cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Epidermal growth factor and transforming growth factor alpha bind differently to the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

A new member of the immunoglobulin superfamily--CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

CTLA-4 is a second receptor for the B cell activation antigen B7

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Interleukin-15 and the regulation of lymphoid homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Complement activation and inhibition in experimental models of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Pathogenesis of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

How IgE upregulates the allergic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Viral immune evasion: a masterpiece of evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

How protozoan parasites evade the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Thrombolysis and intervention in acute myocardial infarction: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Glycoprotein IIb/IIIa antagonism and fibrinolytic therapy for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Tumor-directed targeting of liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Cancer immunogene therapy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Immunology. Catalytic antibody bridges innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Anticocaine catalytic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

The role of interleukin–15 in T–cell migration and activation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Preparation and Characterization of Specific and High-Affinity Monoclonal Antibodies Against Morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Production of functional chimaeric mouse/human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.7.1133

Treatment of acute renal allograft rejection with OKT3 monoclonal antibody

21 January 2018

6

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Structure and Function of Serum and Membrane Immunoglobulin D (IgD)

16 March 2024

14

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

16 March 2024

22

51

6691

BOUCHER Y

1991

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

16 March 2024

23

52

3402

YOKOTA T

1992

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

16 March 2024

40

16

616

BARRY MA

1994

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

16 March 2024

Developmental Biology

49

112

127

SWANSON SJ

2003

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells

16 March 2024

50

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

16 March 2024

52

61

4750

ADAMS GP

2001

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Biotech industry faces new bottleneck

16 March 2024

53

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

ODAC panel gives nod to Bexxar

16 March 2024

65

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically

16 March 2024

66

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

16 March 2024

73

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

16 March 2024

84

59

1236

YANG XD

1999

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice

16 March 2024

85

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

16 March 2024

91

56

2428

MIN HY

1996

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer

16 March 2024

92

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis

16 March 2024

97

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis

16 March 2024

101

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis

16 March 2024

105

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Inflammatory bowel disease

16 March 2024

114

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys

16 March 2024

121

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Mosaic-like organization of IgA protease genes in Neisseria gonorrhoeae generated by horizontal genetic exchange in vivo.

16 March 2024

129

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors

16 March 2024

134

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Human antitransforming growth factor beta(2) monoclonal antibody--a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study

16 March 2024

135

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

16 March 2024

143

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

16 March 2024

147

58

3320

LOPEZ DE MENEZES DE,

1998

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

16 March 2024

156

1 reference

https://api.crossref.org/works/10.1517/14712598.3.7.1133

16 March 2024

Identifiers

1 reference

23 July 2017

1 reference